Schonfeld Strategic Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.48M | Buy |
264,744
+218,349
| +471% | +$2.04M | 0.02% | 787 |
|
|
2025
Q1 | $570K | Buy |
46,395
+25,738
| +125% | +$316K | ﹤0.01% | 1410 |
|
|
2024
Q4 | $273K | Sell |
20,657
-166,806
| -89% | -$2.21M | ﹤0.01% | 1584 |
|
|
2024
Q3 | $3.61M | Sell |
187,463
-73,413
| -28% | -$1.41M | 0.02% | 544 |
|
|
2024
Q2 | $5.36M | Sell |
260,876
-524,768
| -67% | -$10.8M | 0.03% | 456 |
|
|
2024
Q1 | $18.7M | Buy |
785,644
+314,169
| +67% | +$7.48M | 0.12% | 170 |
|
|
2023
Q4 | $10.2M | Buy |
471,475
+253,062
| +116% | +$5.47M | 0.07% | 316 |
|
|
2023
Q3 | $3.17M | Sell |
218,413
-20,154
| -8% | -$293K | 0.02% | 585 |
|
|
2023
Q2 | $4.99M | Buy |
238,567
+91,001
| +62% | +$1.9M | 0.04% | 488 |
|
|
2023
Q1 | $3.12M | Buy |
147,566
+138,466
| +1,522% | +$2.92M | 0.03% | 571 |
|
|
2022
Q4 | $232K | Buy |
+9,100
| New | +$232K | ﹤0.01% | 1895 |
|
|
2022
Q1 | – | Sell |
-12,300
| Closed | -$269K | – | 2684 |
|
|
2021
Q4 | $269K | Sell |
12,300
-63,300
| -84% | -$1.38M | ﹤0.01% | 1489 |
|
|
2021
Q3 | $1.45M | Sell |
75,600
-43,801
| -37% | -$837K | 0.01% | 758 |
|
|
2021
Q2 | $2.05M | Sell |
119,401
-5,101
| -4% | -$87.6K | 0.02% | 669 |
|
|
2021
Q1 | $2.78M | Sell |
124,502
-32,628
| -21% | -$730K | 0.03% | 557 |
|
|
2020
Q4 | $3.5M | Buy |
157,130
+136,314
| +655% | +$3.03M | 0.05% | 455 |
|
|
2020
Q3 | $307K | Buy |
+20,816
| New | +$307K | 0.01% | 1039 |
|